Squarepoint’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Squarepoint’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,215	Closed	-$423K	–	3832
2020 Q4	$423K	Sell	19,215 -50,801	-73%	-$1.12M	﹤0.01%	1936
2020 Q3	$1.26M	Buy	70,016 +54,176	+342%	+$1.12M	0.02%	867
2020 Q2	$402K	Sell	15,840 -39,205	-71%	-$845K	0.01%	1427
2020 Q1	$1.01M	Sell	55,045 -91,078	-62%	-$1.77M	0.03%	716
2019 Q4	$3.22M	Buy	146,123 +103,147	+240%	+$2.08M	0.02%	657
2019 Q3	$617K	Buy	42,976 +18,623	+76%	+$266K	0.01%	1510
2019 Q2	$384K	Buy	+24,353	New	+$331K	﹤0.01%	1814
2019 Q1	–	Sell	-30,721	Closed	-$328K	–	2539
2018 Q4	$328K	Sell	30,721 -18,872	-38%	-$248K	﹤0.01%	1464
2018 Q3	$757K	Buy	+49,593	New	+$722K	0.01%	1117
2016 Q3	–	Sell	-16,300	Closed	-$49K	–	1348
2016 Q2	$49K	Buy	+16,300	New	+$66.9K	﹤0.01%	1026

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Squarepoint's DRNA Position: Q1 2021 in Review

Squarepoint sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2021, closing a stake of 19,215 shares — an estimated $423K sold.

Squarepoint first reported a position in DRNA in Q2 2016 and held it in 10 quarters. The position peaked at $3.22M in Q4 2019. 183 funds tracked by Wall St. Rank hold DRNA as of Q1 2021.

Squarepoint reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Squarepoint sold 19,215 Dicerna Pharmaceuticals, Inc. shares in Q1 2021, an estimated $423K.
Squarepoint first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2016 and held it in 10 quarters.
Squarepoint's Dicerna Pharmaceuticals, Inc. position peaked at $3.22M in Q4 2019.
183 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.